metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer
versus androgen deprivation therapy (ADT)
	docetaxel plus ADT
	NCI E3805 (Scott), 2017 Urol Oncol 2017; 35:123 NEJM NCT00309985	RCT	metastatic, hormone-sensitive prostate cancer				397 / 393	NA	conclusif	demonstrated 39 % decrease in deaths (OS) (PE)
	STAMPEDE docetaxel, 2016 Lancet 2016 Mar 19;387(10024):1163-77. NCT00268476		metastatic, hormone-sensitive prostate cancer				-/-	NA	suggested	suggested 22 % decrease in deaths (OS)
	GETUG-AFU 15, 2013 Lancet Oncol 2013 Feb;14(2):149-58. NCT00104715	RCT	metastatic, hormone-sensitive prostate cancer	docetaxel and androgen-deprivation therapy (ADT)	androgen-deprivation therapy (ADT) alone	patients with metastatic non-castrate prostate cancer	-/-	NA	inconclusive	no statistically significant result
	CHAARTED unpublished Journal of Clinical Oncology NCT00268476		metastatic, hormone-sensitive prostate cancer				-/-	NA	suggested	suggested 28 % decrease in deaths (OS)